Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 10/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13801273 | 0.86 | DRD2 (0.67) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL13801364 | 0.86 | DRD2 (0.55) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL13801372 | 0.86 | DRD2 (0.52) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL13801345 | 0.84 | DRD2 (0.50) | DRD2DRD4DRD3CALCRLCCR5 | |
| SCHEMBL13801360 | 0.84 | DRD2 (0.64) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL13801338 | 0.83 | DRD2 (0.49) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL3962540 | 0.83 | DRD2 (0.47) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL13801361 | 0.82 | DRD2 (0.50) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL13801346 | 0.82 | DRD2 (0.48) | DRD2DRD4DRD3CALCRLTNKS | |
| SCHEMBL13801376 | 0.80 | DRD2 (0.45) | DRD2DRD4DRD3CALCRLTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | DRD2 187/4885DRD4 139/4885DRD3 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.